Optimizing 340B Participation Compliantly While “Waiting and Watching” New Developments
Hospitals and health systems that participate in the federal 340B Drug Pricing Program are currently facing challenges on multiple fronts, including manufacturer restrictions and program audits, legal challenges, and constantly-evolving federal and state requirements for participation.
Article